Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? After all, this has been another stressful and chaotic few days. Usually, we take this opportunity to daydream about weekend plans, but our agenda will be rather limited because we plan to work a wee bit more. That said, we do plan to promenade, when possible, with our new official mascot around the neighborhood. And what about you? This may be a good time to peek inside your pantry and take an inventory. You could tune out the world and read a book or binge-watch something on the telly. Or you could reach out to someone who is feeling especially isolated these days. Well, whatever you do, make the best of it. But be safe. See you soon.

A Chicago hospital treating severe Covid-19 patients with remdesivir, the Gilead Sciences (GILD) antiviral, in a clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned. The trial recruited 125 people with Covid-19 into Gilead’s two Phase 3 clinical trials. Of those, 113 had severe disease. “The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish,” said Kathleen Mullane of the University of Chicago.


On March 21, two days after President Trump first touted chloroquine drugs as a “game changer” in the fight against Covid-19, administration officials privately described what they felt was a “win” in the president’s efforts to build an emergency stockpile of the drugs: a hefty donation of of 3 million pills of Resochin from Bayer. After a brief period of testing, its use in the U.S. was approved on an emergency basis. But sources tell Reuters there is reason to be concerned about the quality of Resochin and its makers, located in India and Pakistan.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!